ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.524,57
-0,41%
S&P 500
5.631,22
0,28%
Dow Jones
40.211,72
0,53%
Euro vs US Dollar
1,09005
0,01%
Bitcoin
62.967,12
-2,91%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Ardelyx Inc (ARDX)

  7. Ardelyx Inc (ARDX) News

ARDX

Ardelyx (ARDX)

Ardelyx Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ARDX
DatumZeitQuelleÜberschriftSymbolFirma
23/05/202322h05GlobeNewswire Inc.Ardelyx, Inc. Reports Employment Inducement GrantsNASDAQ:ARDXArdelyx Inc
17/05/202322h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDXArdelyx Inc
17/05/202313h30GlobeNewswire Inc.Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)NASDAQ:ARDXArdelyx Inc
15/05/202322h05GlobeNewswire Inc.Ardelyx, Inc. Reports Employment Inducement GrantsNASDAQ:ARDXArdelyx Inc
09/05/202314h00GlobeNewswire Inc.Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in AdultsNASDAQ:ARDXArdelyx Inc
03/05/202322h08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ARDXArdelyx Inc
03/05/202322h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDXArdelyx Inc
03/05/202322h02GlobeNewswire Inc.Ardelyx Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ARDXArdelyx Inc
01/05/202314h00GlobeNewswire Inc.Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week ConferenceNASDAQ:ARDXArdelyx Inc
26/04/202322h19Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ARDXArdelyx Inc
26/04/202322h16Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ARDXArdelyx Inc
26/04/202314h00GlobeNewswire Inc.Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023NASDAQ:ARDXArdelyx Inc
18/04/202314h00GlobeNewswire Inc.Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)NASDAQ:ARDXArdelyx Inc
14/04/202322h18Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:ARDXArdelyx Inc
13/04/202322h05GlobeNewswire Inc.Ardelyx, Inc. Reports Employment Inducement GrantsNASDAQ:ARDXArdelyx Inc
12/04/202322h05GlobeNewswire Inc.Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical MeetingsNASDAQ:ARDXArdelyx Inc
02/03/202322h08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ARDXArdelyx Inc
02/03/202322h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDXArdelyx Inc
02/03/202322h02GlobeNewswire Inc.Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateNASDAQ:ARDXArdelyx Inc
28/02/202314h00GlobeNewswire Inc.Ardelyx Publishes First Environmental, Social and Governance (ESG) ReportNASDAQ:ARDXArdelyx Inc
27/02/202314h15GlobeNewswire Inc.Ardelyx to Participate at the Cowen 43rd Annual Health Care ConferenceNASDAQ:ARDXArdelyx Inc
24/02/202323h39Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDXArdelyx Inc
23/02/202314h00GlobeNewswire Inc.Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023NASDAQ:ARDXArdelyx Inc
15/02/202312h10Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDXArdelyx Inc
14/02/202314h26Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ARDXArdelyx Inc
07/02/202322h40Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ARDXArdelyx Inc
02/02/202322h20PR Newswire (US)Ardelyx, Inc. Reports Employment Inducement GrantsNASDAQ:ARDXArdelyx Inc
27/01/202322h19Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ARDXArdelyx Inc
24/01/202322h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDXArdelyx Inc
10/01/202312h02Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ARDXArdelyx Inc
 Showing the most relevant articles for your search:NASDAQ:ARDX

Kürzlich von Ihnen besucht

AMEX
SPY
SPDR S&P 500
NYSE
MRK
Merck
NASDAQ
NVDA
NVIDIA
FX
EURGBP
Euro vs Sterling
USOTC
RHHBY
Roche (QX)
FX
EURUSD
Euro vs US Dollar
NASDAQ
AAPL
Apple
NYSE
KO
Coca Cola
AMEX
XLV
Health Care Select Sector
NASDAQ
AMZN
Amazon.com
DBI
DAX
DAX
NYSE
NKE
Nike
USOTC
ADDYY
Adidas (QX)
TG
TUI1
Tui
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten